U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Jun 26 16:51:19 UTC 2021
Edited
by admin
on Sat Jun 26 16:51:19 UTC 2021
Protein Type RECEPTOR
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
XC55JSP2CX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HISTAMINE H2 RECEPTOR
Common Name English
GASTRIC RECEPTOR I
Common Name English
HH2R
Common Name English
H2R
Common Name English
Code System Code Type Description
PHAROS
P25021
Created by admin on Sat Jun 26 16:51:21 UTC 2021 , Edited by admin on Sat Jun 26 16:51:21 UTC 2021
PRIMARY
UNIPROT
P25021
Created by admin on Sat Jun 26 16:51:21 UTC 2021 , Edited by admin on Sat Jun 26 16:51:21 UTC 2021
PRIMARY
FDA UNII
XC55JSP2CX
Created by admin on Sat Jun 26 16:51:21 UTC 2021 , Edited by admin on Sat Jun 26 16:51:21 UTC 2021
PRIMARY
From To
1_91 1_174
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_4
Related Record Type Details
INVERSE AGONIST->TARGET
INHIBITOR->OFF-TARGET
Radioligand binding assay
BINDING
IC50
INHIBITOR -> TARGET
INVERSE AGONIST->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TRANSPORTER
INHIBITOR -> TARGET
INHIBITOR
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
WEAK INHIBITOR->TARGET
INHIBITOR
Ki
INHIBITOR -> TARGET
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
INHIBITOR -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL